Topic
KEYNOTE-D46/EVOKE-03
1 recent story · updated continuously
Businesswire
Merck and Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Study for Lung Cancer Treatment
health
Just now
